SeaStar Medical Holding Corp
Close on Oct 19, 2026
- Market cap
- $12.70M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | After market close | $600.00K | $-0.91 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | After market close | $500.00K | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 25, 2026 | After market close | $420.00K | $-0.80 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | $200.00K | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | $300.00K | $-0.18 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | After market close | $300.00K | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | After market close | $67.00K | $-0.90 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | After market close | $67.50K | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 22, 2023 | After market close | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 15, 2023 | After market close | – | – | – |
Company guidance
Outlook given with results on May 13, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| net product revenue | 2026 | $2.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements SeaStar Medical filed with the SEC
PRESS RELEASE, DATED OCTOBER 5, 2026
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
SeaStar Medical Reports Second Quarter 2026 Financial Results and
Results of operations · EX-99.1 to Form 8-K
SeaStar Medical Reports First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
SeaStar Medical Announces 1-for-10 Reverse Split
Other events · EX-99.1 to Form 8-K/A
SeaStar Medical Reports Third Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
SeaStar Medical Reports DSMB Recommendation to Continue the
Other events · EX-99.1 to Form 8-K
SeaStar Medical Reports Second Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K/A
SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED JULY 10, 2025
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
SeaStar Medical Announces Positive Nasdaq Listing Determination
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
SeaStar Medical Announces Pricing of Up to $8 Million Public Offering
Material agreement · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
SeaStar Medical Reports First Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED JANUARY 31, 2025
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
January 2025 www.SeaStarMedical.com Nasdaq: ICU Investor Presentation Bringing organ - restoring solutions to critically ill patients
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED JULY 10, 2024
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED JULY 11, 2024
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED APRIL 17, 2024
Results of operations · EX-99.1 to Form 8-K
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
Other events · EX-99.1 to Form 8-K/A
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
Other events · EX-99.1 to Form 8-K
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury
Other events · EX-99.1 to Form 8-K
SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
FDA Issues Approvable Letter for SeaStar Medical’s Selective Cytopheretic Device for Pediatric Patients
Other events · EX-99.1 to Form 8-K
SeaStar Medical Reports Second Quarter 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
SeaStar Medical Reports First Quarter 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
SeaStar Medical Provides Regulatory Update Related to its HDE Application for Pediatric Selective
Other events · EX-99.1 to Form 8-K
SeaStar Medical Reports 2022 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
SeaStar Medical Holding Corporation Closes Initial $3.3 Million Tranche of $9.8 Million Private Placement
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Consequences of Hyperinflammation February 2023 Investor Presentation Exhibit 99.1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
SeaStar Medical to Hold Business Update Conference Call on February 15, 2023
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
DRAFT 3+LHA clean + AL Comments
Other events · EX-99.1 to Form 8-K
SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study a Novel Therapy to Reduce
Other events · EX-99.1 to Form 8-K
SeaStar Medical Completes Business Combination with LMF Acquisition Opportunities
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
The unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2022 and year ended December 31,
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K